Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement Termination

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

Sironax, a clinical-stage biotechnology company, has been recognized by Fierce Biotech as one of the 15 most innovative and promising private biotech companies of 2026. The company is advancing clinical-stage programs including SIR2501 (SARM1 inhibitor), SIR4156 (NAMPT activator), and SIR9900 (RIPK1 inhibitor) for neurodegenerative, metabolic, inflammatory, and immunological diseases. Sironax recently acquired a brain delivery platform to address blood-brain barrier challenges.

Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity

Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights

Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth

The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.

Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450